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Shivji et al. find that the BRCA2 tumor
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Cancer-associated BRCA2 mutations
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polymerase, provoking unscheduled
R-loop accumulation at promoter-
proximal pause sites and triggering DNA
breakage. This mechanism may underlie
genome instability and carcinogenesis
after BRCA2 inactivation.
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The controlled release of RNA polymerase II (RNAPII)
from promoter-proximal pausing (PPP) sites is crit-
ical for transcription elongation in metazoans. We
show that the human tumor suppressor BRCA2 inter-
acts with RNAPII to regulate PPP release, thereby
preventing unscheduled RNA-DNA hybrids (R-loops)
implicated in genomic instability and carcinogenesis.
BRCA2 inactivation by depletion or cancer-causing
mutations instigates RNAPII accumulation and
R-loop accrual at PPP sites in actively transcribed
genes, accompanied by gH2AX formation marking
DNA breakage, which is reduced by ERCC4 endo-
nuclease depletion. BRCA2 inactivation decreases
RNAPII-associated factor 1 (PAF1) recruitment
(which normally promotes RNAPII release) and
diminishes H2B Lys120 ubiquitination, impeding
nascent RNA synthesis. PAF1 depletion phenocop-
ies, while its overexpression ameliorates, R-loop
accumulation after BRCA2 inactivation. Thus, an un-
recognized role for BRCA2 in the transition from pro-
moter-proximal pausing to productive elongation via
augmented PAF1 recruitment to RNAPII is subverted
by disease-causing mutations, provoking R-loop-
mediated DNA breakage in BRCA2-deficient cells.INTRODUCTION
Inherited mutations inactivating the BRCA2 tumor suppressor
gene predispose to cancers of the breast, ovary, pancreas,
prostate, and other tissues (Breast Cancer Linkage Con-
sortium, 1999). Human BRCA2 protein serves as a custodian
of chromosome integrity via the nucleation of multi-protein com-
plexes essential for homologous DNA recombination, replication
fork protection, and cell-cycle control (reviewed in Venkitara-
man, 2014). The chromosomal instability characteristic of
BRCA2-deficient cells has been attributed to loss of these func-
tions, but recent findings show that BRCA2 deficiency also
causes the unscheduled accumulation of RNA-DNA hybrids
(R-loops) (Bhatia et al., 2014) and link R-loop accrual to chromo-
somal structural aberrations in BRCA2-deficient cells (Tan et al.,
2017).Cell Re
This is an open access article undThe mechanism by which BRCA2 deficiency causes R-loop
accumulation remains unclear (Bhatia et al., 2014). R-loops
are normal intermediates during processes like transcription,
replication, or DNA repair, but they also occur when RNA
polymerase II (RNAPII) stalls at nucleotide lesions that arrest
the transcription of DNA templates (Aguilera and Garcı´a-Muse,
2012; Hamperl and Cimprich, 2014; Sollier and Cimprich,
2015). In addition, RNAPII pausing occurs physiologically during
an early step in transcription elongation to efficiently manage
gene expression patterns that suit cellular requirements (Jonkers
and Lis, 2015). Most RNAPII-transcribed genes in metazoan
cells contain a promoter-proximal pause (PPP) site located
20-50 nucleotides downstream of the position where transcrip-
tion begins (Krumm et al., 1995; Rasmussen and Lis, 1993;
Rougvie and Lis, 1988). RNAPII enriched for phosphorylation
on Ser5 in its C-terminal domain (CTD) pauses at these sites after
the synthesis of a short nascent RNA tract (Boehm et al., 2003).
RNAPII release from PPP sites is accompanied by the phosphor-
ylation of Ser2 in its CTD by the kinase cyclin T-CDK9 (Cho et al.,
2001; Marshall et al., 1996), empowering the recruitment of
a protein complex including RNAPII-associated factor 1 (PAF1)
(Chen et al., 2015; Yu et al., 2015). In turn, PAF1 recruitment to
RNAPII triggers events leading to the ubiquitination of histone
H2B on Lys120, a modification that is proposed to open chro-
matin downstream of the transcription complex to facilitate tran-
scription elongation (Van Oss et al., 2016; Wu et al., 2014; Xiao
et al., 2005). Mounting evidence suggests that RNAPII release
from PPP sites is tightly regulated to control mammalian gene
expression (reviewed in Adelman and Lis, 2012).
Inactivation of BRCA1, a tumor suppressor protein that is
functionally and structurally distinct from BRCA2 but cooperates
with it during cellular responses to DNA damage (reviewed in
Venkitaraman, 2014), is also accompanied by unscheduled
R-loop accumulation (Hatchi et al., 2015; Zhang et al., 2017).
A small pool of intracellular BRCA1 interacts with RNAPII (Schle-
gel et al., 2000; Scully et al., 1997). Conflicting reports variously
attribute R-loop formation in BRCA1-deficient cells either to
transcription termination sites at the 30 ends of genes (Hatchi
et al., 2015) via the interaction of BRCA1 with the R-loop resol-
vase senataxin (SETX) (Skourti-Stathaki et al., 2011) or, alterna-
tively, to 50 PPP sites (Zhang et al., 2017) only in certain epithelial
cell types through mechanisms that remain unclear. Moreover,
whether R-loop accrual following BRCA2 inactivation arises
from similar anomalies is not known.
Here, we report an unanticipated role for BRCA2 in the control
of transcription elongation at PPP sites through the enhancedports 22, 1031–1039, January 23, 2018 ª 2017 The Authors. 1031
er the CC BY license (http://creativecommons.org/licenses/by/4.0/).
Figure 1. BRCA2 Deficiency Leads to R-Loop Formation Accompanied by RNAPII Accumulation at the PPP Sites of Classical Paused Genes
(A and B) Immunofluorescence detection of R-loops with S9.6 antibody in HeLa Kyoto cells transfected with either siCtrl (control) or siBRCA2 (A) and BRCA2-
deficient EUFA423 cells (see Figure S1C) and EUFA423 B2 controls complemented with wild-type BRCA2 (B). HeLa cell transfections were carried out for 72 hr
before analysis. Plots show the mean ± SEM from three independent experiments. The two-tailed Student’s t test was performed to determine statistical sig-
nificance between the two groups (**p < 0.01). Scale bars, 10 mm.
(C) Schematic diagram of the ACTB gene showing primer positions (PPP, In1 or In5, pA, and TES) and exon numbers. DRIP analyses with S9.6 antibody in
EUFA423 B2 and EUFA423 (left) and in HeLa Kyoto cells transfected with the indicated siRNA for 72 hr (right) are shown. R-loop digestion by RNase H is shown
as a control. Plots depict the mean ± SEM from three independent experiments. The 2-way ANOVA test was performed for all pairs to determine statistical
significance. Statistically significant differences are indicated (**p < 0.01, left; *p < 0.05, right).
(D) Schematic diagram of the GAPDH gene, showing primer positions (PPP, In5, and TES) and exon numbers. DRIP analyses were performed and depicted as
described in the preceding panels. Statistically significant differences are indicated (*p < 0.05, left; ***p < 0.001, right).
(E) Schematic diagram of the TEFM gene, showing primer positions (PPP, In2 and TES) and exon numbers. DRIP analyses were performed and depicted as
described in the preceding panels. Statistically significant differences are indicated (*p < 0.05, left; **p < 0.01, right).recruitment of PAF1 to RNAPII. BRCA2 inactivation by cancer-
associated mutations or RNAi-mediated depletion subverts this
mechanism, impeding transcription elongation at the PPP sites
of actively transcribed genes, accompanied by R-loop accumu-
lation and DNA breakage mediated by the ERCC4 nuclease. By
contrast, BRCA1 or SETX depletion causes R-loop accumulation
at 30 transcription termination sites, distinguishing the mecha-
nism mediated by BRCA2. Thus, our work identifies an unrecog-
nizedmechanismbywhichBRCA2controls transcription elonga-
tion and suggests that abnormalities in this process instigate
unscheduled R-loop formation and ensuing genomic instability.1032 Cell Reports 22, 1031–1039, January 23, 2018RESULTS
BRCA2 Inactivation Triggers R-Loop and DNA Damage
Accumulation at PPP Sites
Nuclear R-loop accumulation detected by the S9.6 antibody
specific to R-loop structures (Bhatia et al., 2014; Ginno et al.,
2012) increases following BRCA2 inactivation by small inter-
fering RNA (siRNA)-mediated depletion in HeLa Kyoto cells
(Figures 1A and S1A) or by bi-allelic cancer-associated trun-
catingmutations (BRCA27691insAT / 9000insA) in the patient-derived
EUFA423 fibroblast cell line (Howlett et al., 2002) (Figures 1B and
Figure 2. R-Loops Accumulate at the PPP
Sites of Multiple Genes in BRCA2-Deficient
Cells
(A–D) DRIP analysis of MRPL21 (A), CALM3 (B),
VCL (C), and RPL13A (D) genes in EUFA423 B2
and EUFA423 cells. R-loop dissolution byRNaseH
enzyme is shown as a control. Error bars indicate
the mean ± SEM from three independent experi-
ments. The 2-way ANOVA test was performed for
all pairwise comparisons to determine statistical
significance. Statistically significant differences
are indicated (**p < 0.01).
(E) ChIP analysis with gH2AX antibody of the
GAPDH gene in EUFA423 B2 and EUFA423
cells, without or with siRNA targeting ERCC4.
Fold change relative to EUFA423 B2 is plotted.
Error bars indicate the mean ± SEM from three
independent experiments. The 2-way ANOVA test
was performed for all pairwise comparisons to
determine statistical significance. For EUFA423/
ERCC4, significance was determined by com-
parison with EUFA423. Statistically significant
differences are indicated (*p < 0.05, **p < 0.01, and
***p < 0.001).S1C). By contrast, EUFA423 cells stably complemented with
full-length FLAG-tagged BRCA2 (EUFA423 B2) (Hattori et al.,
2011) show no such abnormality (Figure 1B).
We used S9.6 antibody in DNA-RNA immunoprecipitation
(DRIP) analyses (Ginno et al., 2012) to survey R-loop formation
in genomic DNA across the transcription units of seven actively
transcribed genes: ACTB, GAPDH, TEFM, MRPL21, CALM3,
RPL13A, and VCL (Hatchi et al., 2015; Sanz et al., 2016; Zhao
et al., 2016). We analyzed R-loop formation at the 50 PPP sites
of these genes within 200 nt of their transcription start site
(TSS) sequences, as well as at intronic (In) sequences in the
gene body or the 30 sequences associated with transcription-
end sites (TESs). In HeLa Kyoto cells depleted of BRCA2, there
is a statistically significant increase in R-loop formation at the
PPP sites relative to other regions of ACTB, GAPDH and TEFM
(Figure 1C-E), when compared to cells treated with irrelevant
control siRNAs. R-loop formation at the PPP sites of these genes
is also increased in BRCA2-deficient EUFA423 cells, in compar-
ison to EUFA423 B2 isogenic controls reconstituted with BRCA2Cell Repo(Figures 1C–1E). Similar anomalies occur
at the PPP sites ofMRPL21, CALM3, VCL
and RPL13A genes in EUFA423 when
compared to EUFA423 B2 cells (Figures
2A–2D). R-loop detection in these exper-
iments is uniformly suppressed by pre-
treatment with RNase H (Figures 1C–1E
and 2A–2D), an enzyme that digests
R-loops (Ginno et al., 2012).
Interestingly, R-loop accumulation in
the GAPDH transcription unit is accom-
panied by gH2AX formation, a marker
for DNA damage (Figure 2E), most mark-
edly at the PPP site but also at the
adjacent intronic region. Depletion of theendonuclease ERCC4 (Sijbers et al., 1996), which has been
implicated in the cleavage of R-loops to DNA breaks (Sollier
et al., 2014), reduces gH2AX formation (Figure 2E) without signif-
icantly altering R-loop accumulation (Figure S1D). These findings
suggest a mechanism wherein R-loop processing by ERCC4
contributes to genomic instability in BRCA2-deficient cells.
By contrast, depletion of BRCA1 enhances R-loops in a
significant manner at sequences associated with transcription
termination (TES) in ACTB (Figure S2A), consistent with a pre-
vious report (Hatchi et al., 2015), but has little effect on
R-loop formation at PPP sites, in contrast to another study
(Zhang et al., 2017). These observations are distinct from the
defect that we describe for BRCA2 deficiency. Moreover, we
find that BRCA2 depletion increases the accumulation of
SETX (a helicase implicated in R-loop resolution during tran-
scription termination; Skourti-Stathaki et al., 2011) at PPP sites
in ACTB and GAPDH, as well as in their termination sequences,
as detected by chromatin immunoprecipitation (ChIP) (Figures
S2B and S2C). This pattern contrasts with the decreasedrts 22, 1031–1039, January 23, 2018 1033
Figure 3. RNAPII Accumulates at the PPP
Sites of Actively Transcribed Genes
(A) ChIP analyses with RNAPII antibody (N20) of
the ACTB and GAPDH genes in EUFA423 B2 and
EUFA423 cells. Fold change relative to IgG isotype
control is plotted. Plots show the mean ± SEM
from three independent experiments. The 2-way
ANOVA test was performed to determine statisti-
cal significance (*p < 0.05).
(B) ChIP analyses of RNAPII Ser5P in the ACTB
and GAPDH genes in EUFA423 B2 and EUFA423
cells. Data were normalized to input (2%). Plots
show the mean ± SEM from three independent
experiments; the 2-way ANOVA test was per-
formed as above.recruitment of SETX to transcription termination sequences
observed after BRCA1 depletion (Hatchi et al., 2015), again
suggesting that R-loop formation after BRCA2 depletion occurs
via a distinct mechanism.
BRCA2 Inactivation Causes RNAPII Accumulation at
PPP Sites
We next examined the effect of BRCA2 inactivation on the distri-
bution of RNAPII across the ACTB and GAPDH transcription
units using an antibody (N20) (Cheng and Sharp, 2003) capable
of detecting both the non-phosphorylated and CTD Ser2/Ser5
phosphorylated forms of the enzyme. RNAPII was significantly
enriched at PPP sites (as detected by ChIP) in EUFA423 cells
carrying bi-allelic BRCA2 mutations, but not in control
EUFA423 B2 cells reconstituted with full-length BRCA2 (Fig-
ure 3A). ChIP using an antibody that selectively binds to the
Ser5-phosphorylated form of RNAPII (Chapman et al., 2007) re-
veals a more even distribution across both genes (Figure 3B),
although levels are diminished in BRCA2-deficient EUFA423
cells when compared with EUFA423 B2 controls. Collectively,
these findings suggest that the release of RNAPII from PPP sites
in ACTB and GAPDH during transcription elongation is delayed,
but not stopped.
BRCA2 Interacts with RNAPII
The unexpected effect of BRCA2 inactivation on RNAPII distri-
bution prompted us to test whether these proteins interact.
Indeed, RNAPII immunoprecipitated from HeLa Kyoto cell ex-
tracts using the N20 antibody interacts with wild-type BRCA2
(Figure 4A). EUFA423 cells carry the bi-allelic BRCA27691insAT
/ 9000insA truncation mutations, which encode truncated proteins
with predicted molecular weights of 278 kDa (BRCA27691insAT)1034 Cell Reports 22, 1031–1039, January 23, 2018and 358 kDa (BRCA2 9000insA), while con-
trol EUFA423 B2 cells express, in addi-
tion, full-length FLAG-tagged BRCA2
protein of 450 kDa. In EUFA423 B2 cell
extracts (Figure 4B, lanes 1–3), RNAPII
immunoprecipitated with the N20 anti-
body interacts with full-length and the
BRCA29000insA truncated mutant pro-
teins, but as expected in EUFA423 cell
extracts, only with the truncated mutantprotein (Figure 4B, lanes 4–6). Conversely, immunoprecipitation
of BRCA2 from EUFA423 B2 (Figure 4C, lanes 1–3) or EUFA423
(Figure 4C, lanes 4–6) cell extracts demonstrates that full-
length BRCA2, as well as the cancer-associated BRCA29000insA
truncated mutant protein, interact with RNAPII detected by an
antibody (601) against its CTD (Nojima et al., 2015). Recipro-
cally, this RNAPII antibody also co-immunoprecipitates full-
length BRCA2 and the cancer-associated BRCA29000insA
truncated mutant protein (Figure 4D, lanes 1–6). RNAPII that
co-immunoprecipitates with full-length or truncated mutant
BRCA2 is phosphorylated on Ser2 and Ser5 residues in its
CTD (Figures 4C and 4D). Taken together, our findings demon-
strate that RNAPII and BRCA2 interact in human cells and that
the cancer-associated BRCA29000insA truncated mutant protein
retains this interaction.
BRCA2 Inactivation Diminishes PAF1 Recruitment at
PPP Sites
The regulated release of RNAPII from PPP sites requires the
recruitment of PAF1 (Chen et al., 2015; Yu et al., 2015). Strik-
ingly, ChIP analysis of PAF1 after BRCA2 depletion (Figure 5A)
demonstrates reduced recruitment at both the PPP sites and
across the transcription units of the actively transcribed
ACTB and GAPDH genes in comparison with controls. A similar
pattern of reduced PAF1 recruitment also occurs in BRCA2-
deficient EUFA423 cells when compared with EUFA423 B2
control cells complemented with full-length BRCA2 in not
only ACTB and GAPDH (Figure 5B) but also TEFM, CALM3,
VCL, RPL13A, and MRPL21 (Figures S3A–S3E), implicating
the C-terminal region of BRCA2 spanning residues 3,254–
3,418 that is absent from the truncated proteins encoded by
the BRCA27691insAT / 9000insA alleles in this process.
Figure 4. BRCA2 Interacts with RNAPII
(A) IP-western analysis showing the interaction
between RNAPII and BRCA2 after IP with RNAPII
N20 antibody in HeLa Kyoto cell extracts, followed
by western blotting with the indicated antibodies.
(B) A similar analysis showing the interaction be-
tween RNAPII and BRCA2 in EUFA423 B2 and
EUFA423 cells. Bars indicate the relative positions
of the wild-type or truncated form of BRCA2
(mutBRCA2) encoded by BRCA29000insA.
(C) IP-western analysis with BRCA2 (Ab-1) anti-
body showing interaction with phosphorylated
forms of RNAPII in EUFA423 B2 and EUFA423
cells.
(D) Reciprocal IP-western analysis with RNAPII
antibody (601) showing interaction with BRCA2
and mutBRCA2. Inputs represent 10% of the total
cell lysates.
Asterisk (*) denotes a nonspecific band.BRCA2 Inactivation Decreases Histone H2B
Ubiquitination
PAF1 recruitment to RNAPII at PPP sites in turn normally con-
scripts the RNF20/40 E3 ubiquitin ligase complex, which triggers
nucleosome disassembly by ubiquitinating histone H2B on Lys
(K)120, an alteration thought to facilitate transcription elongation
by opening chromatin structure downstream of the active
RNAPII holoenzyme (Van Oss et al., 2016; Wu et al., 2014; Xiao
et al., 2005). The decreased recruitment of PAF1 to the GAPDH
gene following BRCA2 inactivation is accompanied by dimin-
ished histone H2B K120 ubiquitination detected by ChIP in
both BRCA2-depleted cells (compared to controls) (Figure 5C)
and EUFA423 cells (compared to EUFA423 B2 controls) (Fig-
ure 5D). Moreover, decreased PAF1 recruitment to RNAPII and
reduced histone H2B K120 ubiquitination after BRCA2 depletion
are associated with an overall reproducible and quantifiable
decrease in the incorporation of 5-ethynyl uridine (EU) into
nascent RNA detected by immunofluorescence staining (Fig-
ure S4), suggesting that transcription elongation is attenuated
across the transcriptome.
PAF1 Overexpression Ameliorates R-Loop Accrual
following BRCA2 Deficiency
These observations prompted us to test whether reduced PAF1
recruitment to RNAPII is a mechanism causing R-loop accrual at
PPP sites in BRCA2-deficient cells. Indeed, depletion of PAF1
(Figure S1B) triggers R-loop accumulation at PPP sites of
GAPDH detected by DRIP analysis, phenocopying the pattern
induced by BRCA2 depletion (Figure 6A). Combined depletion
of both BRCA2 and PAF1 (Figure S1B) does not significantly
enhance this phenotype (Figure 6A), indicating that they are
epistatic to one another and may thus operate via a common
pathway. R-loop detection in these experiments is markedly
reduced by RNase H (Figure 6A), validating its specificity.
Conversely, overexpression of PAF1 in BRCA2-deficientCell RepoEUFA423 cells (Figure 6B) ameliorates
R-loop accumulation at PPP sites of
GAPDH to a level resembling EUFA423B2 controls (Figure 6C). Thus collectively, our results suggest
that R-loop accrual at PPP sites of actively transcribed genes af-
ter BRCA2 inactivation is mediated by the reduced recruitment
of PAF1 to paused RNAPII.
DISCUSSION
Our work suggests amodel (Figure 6D) in which BRCA2 interacts
with the RNAPII holoenzyme to regulate transcription elongation
by augmenting the recruitment of PAF1 to the PPP sites of
actively transcribed genes. BRCA2 inactivation diminishes
PAF1 recruitment and may consequently reduce downstream
chromatin disassembly that usually facilitates transcription elon-
gation. These abnormalities cause RNAPII to accumulate at PPP
sites, accompanied by the site-specific accrual of unscheduled
R-loops that consequently lead to DNA breaks, via cleavage
by the ERCC4 endonuclease (Sollier et al., 2014). Our findings
suggest that R-loop formation and cleavage into DNA breaks
may occur at multiple loci, raising the possibility that the mech-
anism we report here is a major source of genome damage
following BRCA2 inactivation.
Our model provides a mechanism for the observation that un-
scheduled R-loops accumulate after BRCA2 depletion (Bhatia
et al., 2014), which has attractedmuch topical attention because
of the established links between R-loop accrual and genomic
instability (Aguilera and Garcı´a-Muse, 2012; Hamperl and Cim-
prich, 2014). Indeed, we recently found that the structural chro-
mosomal aberrations typical of BRCA2 deficiency, including
radial chromosomes thought to signify aberrations in DNA repair
by homologous recombination, are reduced by the overexpres-
sion of RNase H1 (Tan et al., 2017). When taken together
with these findings, the work we report here speaks to the notion
that unscheduled R-loop formation caused by defective
transcription elongation is an underlying cause of genomic
instability after BRCA2 inactivation. Indeed, we show here thatrts 22, 1031–1039, January 23, 2018 1035
Figure 5. BRCA2 Inactivation Diminishes
PAF1 Recruitment at PPP Sites and Subse-
quent H2B K120 Ubiquitination
(A and B) ChIP analyses with PAF1 antibody of the
ACTB andGAPDH genes in HeLa Kyoto cells 72 hr
after transfection with siCtrl or siBRCA2 (A) and
EUFA423 B2 and EUFA423 cells (B).
(C and D) ChIP analyses with H2B K120ub anti-
body of GAPDH gene in HeLa Kyoto cells 72 hr
after transfection with siCtrl or siBRCA2 cells (C)
and EUFA423 B2 and EUFA423 cells (D). Fold
change relative to the IgG isotype control antibody
control is plotted.
Plots show the mean ± SEM from three inde-
pendent experiments. Data were normalized to
input (2%). The 2-way ANOVA test was per-
formed for all pairwise comparisons to determine
statistical significance. Statistically significant
differences are indicated (*p < 0.05, **p < 0.01,
and ***p < 0.001).cancer-causing BRCA2 mutations are sufficient to trigger such
defects in the patient-derived EUFA423 cell line.
A small fraction of intracellular BRCA2 binds physically with
BRCA1 (Chen et al., 1998), consistent with evidence that these
tumor-suppressor proteins share at least certain biological func-
tions during the cellular response to DNA damage (reviewed in
Venkitaraman, 2014). However, the distribution and mechanism
of R-loop accrual that we observe following BRCA2 inactivation
appear to differ from that induced by depletion of BRCA1 or
SETX. Our findings are consistent with prior reports (Hatchi
et al., 2015; Zhang et al., 2017) in which siRNA-mediated
BRCA1 depletion causes the accumulation of R-loops at 30 se-
quences associated with the termination of transcription rather
than at PPP sites. Consistent with these observations, such
30 sites are enriched for mutations detected by next-generation
sequencing in the genomes of BRCA1-deficient cancers (Hatchi
et al., 2015). Puzzlingly, however, it has also been recently re-
ported (Zhang et al., 2017) that R-loops accumulate at PPP sites
in the mammary luminal epithelial cells of human BRCA1 muta-
tion carriers and that genetic ablation of NELF-B, a subunit of
the negative elongation factor complex implicated in RNAPII1036 Cell Reports 22, 1031–1039, January 23, 2018pausing (Narita et al., 2003; Ye et al.,
2001) that interacts with BRCA1, reduces
mammary tumorigenesis in a genetically
engineered murine model of Brca1
deficiency (Nair et al., 2016). Thus, while
the mechanisms responsible for R-loop
accrual after BRCA1 inactivation remain
unclear, we identify here a distinct func-
tion for BRCA2 in regulating transcription
elongation by augmenting PAF1 recruit-
ment to RNAPII at PPP sites.
Notably, cancer-associated truncating
mutations that delete a C-terminal region
of the BRCA2 protein retain RNAPII inter-
action but nevertheless diminish PAF1
recruitment to increase RNAPII accumu-lation and R-loop accrual at PPP sites. The C-terminal region
of BRCA2 apparently necessary for PAF1 recruitment is often
deleted in truncating mutations associated with breast and
ovarian cancer (Rebbeck et al., 2015), suggesting its functional
significance in tumor suppression. Thus, an unrecognized func-
tion of BRCA2 in regulating transcription elongation is subverted
by cancer-causing mutations, in turn provoking the site-specific
accumulation of genome-destabilizing R-loops, which can be
cleaved by the ERCC4 endonuclease into DNA breaks. Our
work suggests that unforeseen defects in transcription elonga-
tion—besides previously reported anomalies in DNA repair,
replication, or mitosis—underlie the origins of genome instability
and the pathogenesis of cancers in BRCA2 mutation carriers.
EXPERIMENTAL PROCEDURES
Cell Culture
HeLa Kyoto (Adey et al., 2013), EUFA423 (Howlett et al., 2002), and EUFA423
B2 (stably transfected cell line with FLAG-BRCA2) (Hattori et al., 2011) cell lines
were used in this study. HeLa Kyoto and EUFA423 cells were maintained in
culture in DMEM containing 10% fetal bovine serum (FBS), 1% penicillin/
streptomycin; for EUFA423 B2, G418 (0.75 mg/mL) was added to the medium.
Figure 6. PAF1 Depletion Phenocopies,
while PAF1 Overexpression Ameliorates,
R-Loop Accumulation following BRCA2
Inactivation
(A) DRIP analysis with S9.6 antibody of GAPDH
gene in HeLa Kyoto cells transfected with indi-
cated siRNAs for 72 hr. R-loop dissolution by
RNase H enzyme is shown as a control. Plots show
the mean ± SEM from three independent experi-
ments. The 2-way ANOVA test was performed for
all pairwise comparisons to determine statistical
significance. Statistically significant differences
are indicated (*p < 0.05 and **p < 0.01).
(B) Western blot analysis of the overexpression of
PAF1 in EUFA423 B2 and EUFA423 cells trans-
fected with either 5 mg (lanes 3 and 7) or 10 mg
(lanes 4 and 8) of the PAF1 construct. Cell lysates
were analyzed 24 hr after transfection. Bars indi-
cate the relative positions of the wild-type and
truncated forms of BRCA2 (mutBRCA2).
(C) DRIP analysis ofGAPDH gene (as in A) showing
R-loop reduction after PAF1 overexpression for
24 hr in EUFA423 cells compared to untransfected
EUFA423 or EUFA423 B2 controls. Plots show the
mean ± SEM from three independent experi-
ments. The 2-way ANOVA test was performed for
all pairwise comparisons to determine statistical
significance. Statistically significant differences
are indicated (*p < 0.05; ns, not significant).
(D) Schematic model depicting that BRCA2 regu-
lates transcription elongation by RNA polymerase
II to prevent R-loop accumulation. Normally,
BRCA2 augments the recruitment of PAF1 to
RNAPII paused at PPP sites located 20–60 nt
from transcription start sites (arrow), fostering the
switch to productive transcription elongation (left).
This function is subverted by cancer-causing
BRCA2 mutations (right), diminishing PAF1
recruitment. Consequently, RNAPII accumulates
at PPP sites, triggering the site-specific accrual of
unscheduled R-loops, which are cleaved by the
ERCC4 endonuclease to generate DNA breaks,
triggering genomic instability and carcinogenesis
following BRCA2 inactivation.Cell Lysates, Immunoprecipitation, and Western Blotting
Total cell lysates (TCLs) were prepared from HeLa Kyoto, EUFA423, and
EUFA423 B2 cells using NP40 lysis buffer (Hattori et al., 2011) supplemented
with NaCl (final concentration, 500 mM) and Benzonase (350 m/mL).
Immunoprecipitations (IPs) were performed using TCLs (0.25–0.5 mg) that
were precleared with immunoglobulin G (IgG) and protein A/G beads prior to
incubation with either BRCA2 (Ab-1) or RNAPII antibody (N20 or 601) overnight
at 4C. IPs were collected after incubation with Protein A/G Dynabeads and
washed extensively with Tris buffered saline-0.1% Tween20 (TBST) and
Tris-buffered saline (TBS). The IP targets were identified by western blotting
on 4%–12% Bis-Tris/2-(N-morpholino)ethanesulfonic acid (BT/MES) SDS-
PAGE/transfer overnight on polyvinylidene fluoride (PVDF) Immobilon mem-
branes, blocking/primary antibody (overnight 4C)/secondary antibody in
TBST/5% milk and enhanced chemiluminescence (ECL)/ECL prime chemilu-
minescence detection.
Antibodies
Antibodies used in this study are listed in Table S1.
S9.6 antibody, used to detect RNA-DNA hybrids, was purified from the
mouse hybridoma cell line S9.6 (ATCC- HB8730). Briefly, cell cultures weregrown for7days before supernatantswere centrifuged at 1,5003g for 10mi-
nutes and 0.45-mm filter sterilized. Fractions containing high concentrations
of antibody were dialyzed in 2 L PBS 13 overnight followed by a second dial-
ysis in 500 mL PBS 13/ 50% glycerol for at least 5 hr using an A¨KTA Avant
purifier (GE Healthcare). The antibody was then diluted to a final concentration
of 1 mg/mL and stored at 80C.
Plasmid Transfection
JetPRIME transfection reagent from Polyplus was used according to manu-
facturer’s instructions for transfecting per 15cm dish 5 or 10 mg pcDNA3_PAF1
(a gift from Dr. MatthewMeyerson, Dana-Farber Cancer Institute, Boston, MA,
USA; Addgene plasmid 11059) (Rozenblatt-Rosen et al., 2005) as indicated.
siRNA Transfection
siRNAs were transfected using a standard calcium phosphate transfection
protocol (Lossaint et al., 2013). siRNAs used were Negative Control siRNA
(1027310, QIAGEN), human BRCA2 (ON-TARGET plus SMARTpool, L-003462-
00, Dharmacon), human BRCA1 (50-GGAACCUGUCUCCACAAAG-30), human
ERCC4 (ON-TARGET plus SMARTpool, L-019946-00-0005, Dharmacon), and
human PAF1 (ON-TARGET plus SMARTpool, M-020349-01, Dharmacon).Cell Reports 22, 1031–1039, January 23, 2018 1037
ChIP
ChIP was performed as described previously (Hatchi et al., 2015). Briefly, cells
were crosslinked in DMEM containing 1% formaldehyde (Sigma, F8775)
at room temperature for 10 min with rotation. The crosslinking reaction was
stopped by adding glycine (Sigma, G8898) to a final concentration of
0.125 M for 5 min at room temperature. After two washes with PBS, cells
were collected in 5 mL PBS and centrifuged at 1,500 rpm for 5 min. Cell pellets
were lysed in 5 mM EDTA, 50 mM Tris-HCl (pH 8.0), and 1% SDS supple-
mented with protease and phosphatase inhibitors. Total cell lysates were son-
icated (Bioruptor, Diagenode) to obtain chromatin fragments of an average
length of 200–800 bp and then centrifuged at 10,000 rpm for 10 min at 4C.
10 mg chromatin was diluted 10-fold with 5 mM EDTA, 50 mM Tris-HCl
(pH 8.0), 0.5% NP-40, and 200 mM NaCl supplemented with protease and
phosphatase inhibitors. Chromatin extractswere preclearedwith proteinGDy-
nabeads (Thermo Fisher) for 40 min. The precleared chromatin was incubated
overnight with gentle rotationwith antibodies or control antibody. The following
day, antibodies were captured by adding 20uL of beads and incubated at 4C
with rotation for 2 hr. Immunoprecipitates were washed with: 13: 20 mM Tris-
HCl (pH 8), 2 mM EDTA, 0.1% SDS, 1% Triton X-100, and 165 mM NaCl; 13:
20 mM Tris-HCl (pH 8), 2 mM EDTA, 0.1% SDS, 1% Triton X-100, and 500 mM
NaCl; 13: 10 mM Tris-HCl (pH 8), 1 mM EDTA, 1% NP-40, 1% Na-deoxycho-
late, and 250 mM LiCl; 13: 50 mM HEPES (pH 7.6), 1 mM EDTA, 1% NP-40,
0.7% Na-deoxycholate, and 500 mM LiCl; 23 with Tris-EDTA (TE) (10 mM
Tris-HCl [pH7.5] and 1 mM EDTA). After the final wash, DNA was eluted with
150 mL of 0.1 M sodium carbonate, 1% SDS at 65C for 30 min with
1,200 rpm agitation. To reverse crosslink, 6 mL of 5 M NaCl and 2 mL
proteinase K (20 mg/mL) were added and incubated at 65Cwith gentle agita-
tion for at least 3 hr. DNA was purified using a PCR purification kit (QIAGEN)
and analyzed by qPCR using SYBR green mix (Roche) with the primers of
interest. For gH2AX ChIP, the values were normalized to EUFA423 B2.
DRIP
Genomic DNA, extracted with a previously described phenol/chloroform pro-
cedure (Bhatia et al., 2014;Ginnoet al., 2012),wasdigestedat 37Cwitha cock-
tail of restriction enzymes (20U/L EcoRI, 20UHindIII, 20U XbaI, 25USSPI, and
10 U BsrGI per 50mg DNA) in buffer 2.1 (NEB) with or without RNase H (5 U/mL,
NEB). Following a second DNA purification step with standard phenol/chloro-
form procedure, 10 mg of digested DNA was diluted in 900 mL of TE buffer
(5 mM EDTA and 50 mM Tris HCl [pH 8]) and 100 mL of 10X DRIP buffer
(100 mM NaH2PO4, 1.4 M NaCl, and 0.5% Triton-X) was added. Chromatin
was precleared with 20 mL protein G Dynabeads for 40 min at 4C. Then,
10 mg S9.6 antibody was added to the supernatant and incubated at 4C over-
night with gentle rotation. Antibody capture was done with 20 mL beads and in-
cubation at 4C for 2 hr. Immunoprecipitates were washed twice with 13 DRIP
buffer, andonce in 13DRIPbuffer + 330mMNaCl. After the lastwash,DNAwas
eluted by adding DRIP elution buffer (50 mM Tris-HCl [pH 8], 10 mMEDTA, and
0.5%SDS)and incubatedat 65C for45min.DNAwasfinally purifiedusingPCR
purification kit (QIAGEN) and analyzed by qPCR with SYBR green mix (Roche).
Primers
Primers used in this study are listed in Table S2.
Immunofluorescence for R-Loop Detection
The appropriate number of cells was plated on coverslips the day before
transfection and after transfection fixed in cold methanol for 10 min at
20C, followed by incubation for 1 min in cold acetone at room temperature.
The coverslips were then quickly washed in saline sodium citrate (SSC) 43
buffer thrice and then incubated for 30 min in SSC 43, 3% BSA to prevent
nonspecific interaction. Primary antibodies were incubated overnight at 4C
(S9.6 1/100, purified in house). After three washes with PBS-tween 0.05%,
coverslips were incubated at room temperature with secondary antibodies
Alexa 488 and Alexa Fluor 568 (Molecular Probes, 1/500). Coverslips were
mounted with DAKO mounting medium (S3023) supplemented with DAPI
(1.5 mg/mL, D9542, Sigma) after three additional washes with PBS-tween
0.05%. Stained cells were imaged on a Zeiss 880 confocal microscope.
Maximum projections of the z stacks of each field were analyzed using Fiji soft-
ware (https://fiji.sc/). Intensity was calculated using a DAPI mask.1038 Cell Reports 22, 1031–1039, January 23, 2018EU Incorporation and IF
Cells were treated with a modified nucleotide (EU; E10345) at 2 mM concen-
tration for 30 min prior to fixation (Jao and Salic, 2008) and detection with
the Click-iT RNA Alexa Fluor 594 Imaging Kit (C10330, Thermo Fisher) accord-
ing to the manufacturer’s instructions. Image acquisition and analysis were
performed as described above.
Statistical Analysis
Statistical significance was determined using a two-tailed Student’s t test
for testing significance between two groups. For ChIP and DRIP analysis,
statistical significances were performed using two-way analysis of variance
(2-way ANOVA) followed by a Bonferroni correction. All pairwise comparisons
were tested, but only statistically significant differences are indicated with
asterisks in the figures. All tests were performed using GraphPad Prism 5.0.
See Table S3 for more information.
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